In a Parkinson’s disease study, the SDMT and MoCA scales were considered appropriate tools for identifying cognitive features regulated by amyloid-β (Aβ) and tau protein phosphorylation in established synucleinopathies (Fiorenzato et al., 2018). The gene discussed is MAPT; the disease is Parkinson disease.